AI-generated analysis. Always verify with the original filing.
BeyondSpring Inc. announced financial results for the full year ended December 31, 2025, reporting net loss from continuing operations of $8.7 million and cash, cash equivalents, and short-term investments of $12.6 million. The company highlighted Phase 3 survival benefits for Plinabulin in EGFR wild-type NSCLC from the DUBLIN-3 study and plans for the confirmatory DUBLIN-4 trial.
Event Type
Disclosure
Mandatory
Variant
8-K
. Results of Operations and Financial Condition. On March 25, 2026, BeyondSpring Inc. (the “Company”) issued a press release announcing its financial results fo
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Exhibit 99.1 Press release, dated March 25, 2026. 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Research and development expenses | $4.40 | GAAP |
| General and administrative expenses | $4.60 | GAAP |
| Net loss from continuing operations | $8.70 | GAAP |